- Home
- YRD vs CELC Comparison
YRD vs CELC Comparison
Compare YRD & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YRD
- CELC
- Stock Information
- Founded
- YRD 2012
- CELC 2011
- Country
- YRD China
- CELC United States
- Employees
- YRD N/A
- CELC N/A
- Industry
- YRD Finance: Consumer Services
- CELC Medical Specialities
- Sector
- YRD Finance
- CELC Health Care
- Exchange
- YRD Nasdaq
- CELC Nasdaq
- Market Cap
- YRD 415.5M
- CELC 489.7M
- IPO Year
- YRD 2015
- CELC 2017
- Fundamental
- Price
- YRD $4.77
- CELC $12.86
- Analyst Decision
- YRD
- CELC Strong Buy
- Analyst Count
- YRD 0
- CELC 6
- Target Price
- YRD N/A
- CELC $29.17
- AVG Volume (30 Days)
- YRD 194.1K
- CELC 232.9K
- Earning Date
- YRD 11-20-2024
- CELC 11-14-2024
- Dividend Yield
- YRD 4.14%
- CELC N/A
- EPS Growth
- YRD N/A
- CELC N/A
- EPS
- YRD 2.95
- CELC N/A
- Revenue
- YRD $802,340,579.00
- CELC N/A
- Revenue This Year
- YRD N/A
- CELC N/A
- Revenue Next Year
- YRD N/A
- CELC N/A
- P/E Ratio
- YRD $1.62
- CELC N/A
- Revenue Growth
- YRD 19.51
- CELC N/A
- 52 Week Low
- YRD $2.94
- CELC $11.51
- 52 Week High
- YRD $9.20
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- YRD 43.26
- CELC 42.58
- Support Level
- YRD $4.66
- CELC $11.94
- Resistance Level
- YRD $4.93
- CELC $13.14
- Average True Range (ATR)
- YRD 0.31
- CELC 0.51
- MACD
- YRD 0.02
- CELC 0.07
- Stochastic Oscillator
- YRD 38.24
- CELC 58.70
About YRD Yiren Digital Ltd.
Yiren Digital Ltd is an advanced, AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.